{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:27:36Z","timestamp":1772166456842,"version":"3.50.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01AI157962"],"award-info":[{"award-number":["U01AI157962"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Outside of sub-Saharan Africa,\n                      <jats:italic>Plasmodium vivax<\/jats:italic>\n                      has become the dominant species of malaria. Focal mass drug administration (fMDA) is a potential strategy to support elimination efforts, but controlled studies are lacking.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The FocaL mass drug Administration for\n                      <jats:italic>Plasmodium vivax<\/jats:italic>\n                      Malaria Elimination (FLAME) study is a 3-year cluster randomized controlled trial to determine the impact and safety of fMDA to reduce\n                      <jats:italic>P. vivax<\/jats:italic>\n                      transmission. The study will be conducted in Loreto, Peru, where standard interventions have reduced\n                      <jats:italic>P. vivax<\/jats:italic>\n                      cases, but transmission persists due to a high proportion of subclinical infections. Thirty low transmission communities (API\u2009&lt;\u2009250 cases\/1000 population) will be randomized 1:1 to fMDA versus control using a restricted randomization. All communities will receive Peruvian national standard malaria control measures. In the intervention arm, high-risk individuals (living within 200 m of a\n                      <jats:italic>P. vivax<\/jats:italic>\n                      case reported in the prior 2 years) without contraindication to study medications, including G6PD deficiency, will receive three cycles of fMDA over a 2-year period. Each cycle will include two rounds of directly observed therapy delivered 2 months apart. The fMDA regimen will include 25 mg\/kg chloroquine (CQ) plus a single 300 mg dose of tafenoquine (TQ) for individuals age\u2009\u2265\u200916 years, and 25 mg\/kg of CQ plus 7 days of 0.5 mg\/kg\/day of primaquine (PQ) if younger. The primary outcome is the cumulative incidence of symptomatic\n                      <jats:italic>P. vivax<\/jats:italic>\n                      malaria. The sample size provides 80% power to detect at least a 68% relative reduction in cumulative\n                      <jats:italic>P. vivax<\/jats:italic>\n                      incidence, based on alpha of 0.05 and a coefficient of variation (\n                      <jats:italic>k<\/jats:italic>\n                      ) of 0.87. Secondary outcomes include safety, cost-effectiveness, and infection prevalence and seroprevalence which will be assessed in annual cross-sectional surveys. Safety will be assessed in passive and active pharmacovigilance, including post-treatment screening for G6PD-associated hemolysis by assessing for anemia and hematuria in a sample.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>\n                      The trial will generate evidence regarding fMDA for\n                      <jats:italic>P. vivax<\/jats:italic>\n                      and inform malaria elimination efforts in Peru and similarly endemic settings. Findings will be disseminated in peer-reviewed publications and through stakeholder meetings in Peruvian and international research forums.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Clinicaltrials.gov NCT05690841. This trial was registered on 09 January 2023. Peruvian Clinical Trial Registry (REPEC) 020\u201323. This trial was registered on 21 February 2024.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-025-09112-1","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T13:55:21Z","timestamp":1760450121000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["FocaL mass drug administration for Plasmodium vivax malaria elimination (FLAME): study protocol for an open-label cluster randomized controlled trial in Peru"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2700-9489","authenticated-orcid":false,"given":"Sydney R.","family":"Fine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Soto Calle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrid","family":"Altamirano Quiroz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Rodriquez Ferruci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo","family":"Manrique","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Carrasco Escobar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jade","family":"Benjamin-Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Auburn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ric N.","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Greenhouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Kevin","family":"Baird","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo J.","family":"Domingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle E.","family":"Roh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angel","family":"Rosas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Llanos-Cuentas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle S.","family":"Hsiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"9112_CR1","unstructured":"World Health Organization. (2022). WHO guidelines for malaria, 3 June 2022. World Health Organization. https:\/\/apps.who.int\/iris\/handle\/10665\/354781.\u00a011 Aug 2023. License: CC BY-NC-SA 3.0 IGO.\u00a0"},{"issue":"9895","key":"9112_CR2","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/S0140-6736(13)60310-4","volume":"382","author":"C Cotter","year":"2013","unstructured":"Cotter C, Sturrock HJW, Hsiang MS, Liu J, Phillips AA, Hwang J, et al. The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet. 2013;382(9895):900\u201311.","journal-title":"Lancet"},{"issue":"6","key":"9112_CR3","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.pt.2020.03.009","volume":"36","author":"RN Price","year":"2020","unstructured":"Price RN, Commons RJ, Battle KE, Thriemer K, Mendis K. Plasmodium vivax in the Era of the Shrinking P. falciparum Map. Trends Parasitol. 2020;36(6):560\u201370.","journal-title":"Trends Parasitol."},{"key":"9112_CR4","unstructured":"Towards the elimination of Plasmodium vivax malaria: implementing the radical cure-PMC. [cited 2023 Aug 11]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC8064598\/"},{"issue":"1","key":"9112_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-10-297","volume":"10","author":"NJ White","year":"2011","unstructured":"White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J. 2011;10(1):297.","journal-title":"Malar J"},{"issue":"4","key":"9112_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003560","volume":"18","author":"S Auburn","year":"2021","unstructured":"Auburn S, Cheng Q, Marfurt J, Price RN. The changing epidemiology of Plasmodium vivax: insights from conventional and novel surveillance tools. PLoS Med. 2021;18(4):e1003560.","journal-title":"PLoS Med"},{"issue":"4","key":"9112_CR7","doi-asserted-by":"publisher","first-page":"e00011","DOI":"10.1128\/CMR.00011-19","volume":"32","author":"JK Baird","year":"2019","unstructured":"Baird JK. 8-Aminoquinoline therapy for latent malaria. Clin Microbiol Rev. 2019;32(4):e00011-19.","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"9112_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-019-1386-6","volume":"17","author":"RJ Commons","year":"2019","unstructured":"Commons RJ, Simpson JA, Thriemer K, Chu CS, Douglas NM, Abreha T, et al. The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide antimalarial resistance network systematic review and individual patient data meta-analysis. BMC Med. 2019;17(1):151.","journal-title":"BMC Med"},{"issue":"8","key":"9112_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002379","volume":"14","author":"NM Douglas","year":"2017","unstructured":"Douglas NM, Poespoprodjo JR, Patriani D, Malloy MJ, Kenangalem E, Sugiarto P, et al. Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: a hospital-based cohort study. PLoS Med. 2017;14(8):e1002379.","journal-title":"PLoS Med"},{"issue":"9","key":"9112_CR10","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S1473-3099(18)30348-7","volume":"18","author":"RJ Commons","year":"2018","unstructured":"Commons RJ, Simpson JA, Thriemer K, Humphreys GS, Abreha T, Alemu SG, et al. The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide antimalarial resistance network systematic review and individual patient pooled meta-analysis. Lancet Infect Dis. 2018;18(9):1025\u201334.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"9112_CR11","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12936-023-04670-8","volume":"22","author":"G Newby","year":"2023","unstructured":"Newby G, Cotter C, Roh ME, Harvard K, Bennett A, Hwang J, et al. Testing and treatment for malaria elimination: a systematic review. Malar J. 2023;22(1):254.","journal-title":"Malar J"},{"key":"9112_CR12","unstructured":"World Health Organization. The role of mass drug administration, mass screening and treatment, and focal screening and treatment for malaria: recommendations. 2015. Available from: https:\/\/iris.who.int\/handle\/10665\/338500.\u00a0cited 10 Mar 2023."},{"key":"9112_CR13","unstructured":"ZD S, MP S, MC B, AL B, J H, K L, et al. Mass drug administration for malaria transmission reduction [Internet]. Zenodo; 2022 Apr [cited 2023 Aug 11]. Available from: https:\/\/zenodo.org\/record\/6499958"},{"issue":"1","key":"9112_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-019-2877-9","volume":"18","author":"KA Baltzell","year":"2019","unstructured":"Baltzell KA, Maglior A, Bangu K, Mngadi N, Prach LM, Whittemore B, et al. \u201cWe were afraid of the lion that has roared next to us\u201d; community response to reactive focal mass drug administration for malaria in Eswatini (formerly Swaziland). Malar J. 2019;18(1):238.","journal-title":"Malar J"},{"issue":"1","key":"9112_CR15","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12936-021-03679-1","volume":"20","author":"KW Roberts","year":"2021","unstructured":"Roberts KW, Smith Gueye C, Baltzell K, Ntuku H, McCreesh P, Maglior A, et al. Community acceptance of reactive focal mass drug administration and reactive focal vector control using indoor residual spraying, a mixed-methods study in Zambezi region, Namibia. Malar J. 2021;20(1):162.","journal-title":"Malar J"},{"key":"9112_CR16","doi-asserted-by":"crossref","unstructured":"White MT, Walker P, Karl S, Hetzel MW, Freeman T, Waltmann A, et al. Mathematical modelling of the impact of expanding levels of malaria control interventions on Plasmodium vivax. Nat Commun. 2018;9(1):3300.","DOI":"10.1038\/s41467-018-05860-8"},{"issue":"6","key":"9112_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049050","volume":"12","author":"H Ntuku","year":"2022","unstructured":"Ntuku H, Smith Gueye C, Scott V, Njau J, Whittemore B, Zelman B, et al. Cost and cost effectiveness of reactive case detection (RACD), reactive focal mass drug administration (rfMDA) and reactive focal vector control (RAVC) to reduce malaria in the low endemic setting of Namibia: an analysis alongside a 2\u00d72 factorial design cluster randomised controlled trial. BMJ Open. 2022;12(6):e049050.","journal-title":"BMJ Open"},{"issue":"1","key":"9112_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4269\/ajtmh.14-0254","volume":"93","author":"G Newby","year":"2015","unstructured":"Newby G, Hwang J, Koita K, Chen I, Greenwood B, von Seidlein L, et al. Review of mass drug administration for malaria and its operational challenges. The American Society of Tropical Medicine and Hygiene. 2015;93(1):125\u201334 (Jul 8;).","journal-title":"The American Society of Tropical Medicine and Hygiene"},{"issue":"1","key":"9112_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-51","volume":"13","author":"A Kondrashin","year":"2014","unstructured":"Kondrashin A, Baranova AM, Ashley EA, Recht J, White NJ, Sergiev VP. Mass primaquine treatment to eliminate vivax malaria: lessons from the past. Malar J. 2014;13(1):51.","journal-title":"Malar J"},{"issue":"1","key":"9112_CR20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1186\/1475-2875-12-383","volume":"12","author":"MS Hsiang","year":"2013","unstructured":"Hsiang MS, Hwang J, Tao AR, Liu Y, Bennett A, Shanks GD, et al. Mass drug administration for the control and elimination of Plasmodium vivax malaria: an ecological study from Jiangsu province, China. Malar J. 2013;12(1):383.","journal-title":"Malar J"},{"key":"9112_CR21","doi-asserted-by":"crossref","unstructured":"Robinson LJ, Wampfler R, Betuela I, Karl S, White MT, Li Wai Suen CSN, et al. Strategies for understanding and reducing the Plasmodium vivax and Plasmodium ovale hypnozoite reservoir in Papua New Guinean children: a randomised placebo-controlled trial and mathematical model. von Seidlein L, editor. PLoS Med. 2015;12(10):e1001891.","DOI":"10.1371\/journal.pmed.1001891"},{"issue":"3","key":"9112_CR22","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.4269\/ajtmh.20-0186","volume":"103","author":"RJ Commons","year":"2020","unstructured":"Commons RJ, Simpson JA, Watson J, White NJ, Price RN. Estimating the proportion of Plasmodium vivax recurrences caused by relapse: a systematic review and meta-analysis. Am J Trop Med Hyg. 2020;103(3):1094\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"9112_CR23","doi-asserted-by":"publisher","first-page":"e04692","DOI":"10.7554\/eLife.04692","volume":"3","author":"MT White","year":"2014","unstructured":"White MT, Karl S, Battle KE, Hay SI, Mueller I, Ghani AC. Modelling the contribution of the hypnozoite reservoir to Plasmodium vivax transmission. eLife. 2014;3:e04692.","journal-title":"eLife."},{"issue":"1","key":"9112_CR24","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1038\/s41467-018-05860-8","volume":"9","author":"MT White","year":"2018","unstructured":"White MT, Walker P, Karl S, Hetzel MW, Freeman T, Waltmann A, et al. Mathematical modelling of the impact of expanding levels of malaria control interventions on Plasmodium vivax. Nat Commun. 2018;9(1):3300.","journal-title":"Nat Commun"},{"key":"9112_CR25","unstructured":"mpac-april2019-session7-erg-mass-admnistration-drug-report.pdf [Internet]. [cited 2023 Aug 11]. Available from: https:\/\/www.who.int\/docs\/default-source\/malaria\/mpac-documentation\/mpac-april2019-session7-erg-mass-admnistration-drug-report.pdf?sfvrsn=629b9e55_2"},{"key":"9112_CR26","unstructured":"Ministerio de Salud (Per\u00fa). Documento T\u00e9cnico: Plan Hacia la Eliminaci\u00f3n del la Malaria en el Per\u00fa 2022-2030. Lima: Ministerio de Salud; 2022."},{"issue":"7","key":"9112_CR27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/14656566.2022.2058394","volume":"23","author":"A Llanos-Cuentas","year":"2022","unstructured":"Llanos-Cuentas A, Manrrique P, Rosas-Aguirre A, Herrera S, Hsiang MS. Tafenoquine for the treatment of Plasmodium vivax malaria. Expert Opin Pharmacother. 2022;23(7):759\u201368.","journal-title":"Expert Opin Pharmacother"},{"issue":"346","key":"9112_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e7586","volume":"8","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;8(346):e7586.","journal-title":"BMJ"},{"issue":"1","key":"9112_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-144","volume":"13","author":"KE Battle","year":"2014","unstructured":"Battle KE, Karhunen MS, Bhatt S, Gething PW, Howes RE, Golding N, et al. Geographical variation in Plasmodium vivax relapse. Malar J. 2014;13(1):144.","journal-title":"Malar J"},{"key":"9112_CR30","unstructured":"Rodriguez Ferruci, Hugo. Plan de Eliminaci\u00f3n de la Malaria en el Per\u00fa, avances y desaf\u00edos operativos [PowerPoint presentation]. Iquitos, Peru: GERESA; 2024."},{"issue":"3","key":"9112_CR31","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJMoa1802537","volume":"380","author":"A Llanos-Cuentas","year":"2019","unstructured":"Llanos-Cuentas A, Lacerda MVG, Hien TT, V\u00e9lez ID, Namaik-larp C, Chu CS, et al. Tafenoquine versus Primaquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019;380(3):229\u201341.","journal-title":"N Engl J Med"},{"key":"9112_CR32","unstructured":"World malaria report 2022 [Internet]. [cited 2023 Aug 1]. Available from: https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2022"},{"issue":"1","key":"9112_CR33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12936-017-1957-y","volume":"16","author":"A Rosas-Aguirre","year":"2017","unstructured":"Rosas-Aguirre A, Guzman-Guzman M, Gamboa D, Chuquiyauri R, Ramirez R, Manrique P, et al. Micro-heterogeneity of malaria transmission in the Peruvian Amazon: a baseline assessment underlying a population-based cohort study. Malar J. 2017;16(1):312.","journal-title":"Malar J"},{"key":"9112_CR34","doi-asserted-by":"crossref","unstructured":"Carrasco-Escobar G, Gamboa D, Castro MC, Bangdiwala SI, Rodriguez H, Contreras-Mancilla J, et al. Micro-epidemiology and spatial heterogeneity of P. vivax parasitaemia in riverine communities of the Peruvian Amazon: a multilevel analysis. Sci Rep. 2017;7(1):8082.","DOI":"10.1038\/s41598-017-07818-0"},{"issue":"Supplement_2","key":"9112_CR35","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.1093\/infdis\/jiaa496","volume":"223","author":"A Rosas-Aguirre","year":"2021","unstructured":"Rosas-Aguirre A, Moreno M, Moreno-Gutierrez D, Llanos-Cuentas A, Saavedra M, Contreras-Mancilla J, et al. Integrating parasitological and entomological observations to understand malaria transmission in Riverine Villages in the Peruvian Amazon. J Infect Dis. 2021;223(Supplement_2):S99-110.","journal-title":"J Infect Dis"},{"issue":"3","key":"9112_CR36","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1056\/NEJMoa1710775","volume":"380","author":"MVG Lacerda","year":"2019","unstructured":"Lacerda MVG, Llanos-Cuentas A, Krudsood S, Lon C, Saunders DL, Mohammed R, et al. Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019;380(3):215\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"9112_CR37","first-page":"taz023","volume":"26","author":"CS Chu","year":"2019","unstructured":"Chu CS, Freedman DO. Tafenoquine and G6PD: a primer for clinicians. J Travel Med. 2019;26(4):taz023.","journal-title":"J Travel Med."},{"issue":"11","key":"9112_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001339","volume":"9","author":"RE Howes","year":"2012","unstructured":"Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9(11):e1001339.","journal-title":"PLoS Med"},{"issue":"1","key":"9112_CR39","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12936-017-1889-6","volume":"16","author":"JG Dombrowski","year":"2017","unstructured":"Dombrowski JG, Souza RM, Curry J, Hinton L, Silva NRM, Grignard L, et al. G6PD deficiency alleles in a malaria-endemic region in the Western Brazilian Amazon. Malar J. 2017;16(1):253.","journal-title":"Malar J"},{"issue":"5","key":"9112_CR40","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1590\/0074-0276140123","volume":"109","author":"WM Monteiro","year":"2014","unstructured":"Monteiro WM, Val FFA, Siqueira AM, Franca GP, Sampaio VS, Melo GC, et al. G6PD deficiency in Latin America: systematic review on prevalence and variants. Mem Inst Oswaldo Cruz. 2014;109(5):553\u201368.","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"5","key":"9112_CR41","doi-asserted-by":"publisher","first-page":"542","DOI":"10.4269\/ajtmh.2003.69.542","volume":"69","author":"N Ponsa","year":"2003","unstructured":"Ponsa N, Sattabongkot J, Kittayapong P, Eikarat N, Coleman RE. Transmission-blocking activity of tafenoquine (WR-238605) and artelinic acid against naturally circulating strains of Plasmodium vivax in Thailand. Am J Trop Med Hyg. 2003;69(5):542\u20137.","journal-title":"Am J Trop Med Hyg"},{"key":"9112_CR42","doi-asserted-by":"crossref","unstructured":"Graves PM, Choi L, Gelband H, Garner P. Primaquine or other 8\u2010aminoquinolines for reducing Plasmodium falciparum transmission. Cochrane Database of Systematic Reviews. 2018 [cited 2023 Mar 28];(2). Available from: https:\/\/www.cochranelibrary.com\/cdsr\/doi\/doi.org\/10.1002\/14651858.CD008152.pub5\/full","DOI":"10.1002\/14651858.CD008152.pub5"},{"issue":"3","key":"9112_CR43","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/cid\/ciy939","volume":"69","author":"JS McCarthy","year":"2019","unstructured":"McCarthy JS, Smith B, Reid M, Berman J, Marquart L, Dobbin C, et al. Blood schizonticidal activity and safety of tafenoquine when administered as chemoprophylaxis to healthy, nonimmune participants followed by blood stage Plasmodium falciparum challenge: a randomized, double-blind, placebo-controlled phase 1b study. Clin Infect Dis. 2019;69(3):480\u20136 (Jul 18;).","journal-title":"Clin Infect Dis"},{"issue":"11","key":"9112_CR44","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1093\/cid\/ciad075","volume":"76","author":"BE Barber","year":"2023","unstructured":"Barber BE, Abd-Rahman AN, Webster R, Potter AJ, Llewellyn S, Marquart L, et al. Characterizing the blood-stage antimalarial activity of tafenoquine in healthy volunteers experimentally infected with Plasmodium falciparum. Clin Infect Dis. 2023;76(11):1919\u201327.","journal-title":"Clin Infect Dis"},{"key":"9112_CR45","unstructured":"Webster R, Mitchell H, Peters JM, Heunis J, O\u2019Neill B, Gower J, et al. Transmission blocking activity of low dose tafenoquine in healthy volunteers experimentally infected with Plasmodium falciparum. medRxiv; 2022 [cited 2023 Aug 11]. p. 2022.03.15.22272229. Available from: https:\/\/www.medrxiv.org\/content\/doi.org\/10.1101\/2022.03.15.22272229v1"},{"issue":"6","key":"9112_CR46","doi-asserted-by":"publisher","first-page":"951","DOI":"10.4269\/ajtmh.2006.74.951","volume":"74","author":"NJ Elmes","year":"2006","unstructured":"Elmes NJ, Bennett SM, Abdalla H, Carthew TL, Edstein MD. Lack of sex effect on the pharmacokinetics of primaquine. Am J Trop Med Hyg. 2006;74(6):951\u20132.","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"9112_CR47","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/j.1365-2125.1993.tb05685.x","volume":"35","author":"G Edwards","year":"1993","unstructured":"Edwards G, McGrath CS, Ward SA, Supanaranond W, Pukrittayakamee S, Davis TM, et al. Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. Br J Clin Pharmacol. 1993;35(2):193\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"9112_CR48","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1128\/AAC.03829-14","volume":"59","author":"P Jittamala","year":"2014","unstructured":"Jittamala P, Pukrittayakamee S, Ashley EA, Nosten F, Hanboonkunupakarn B, Lee SJ, et al. Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. Antimicrob Agents Chemother. 2014;59(1):505\u201313.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9220","key":"9112_CR49","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/S0140-6736(00)02352-7","volume":"355","author":"B Lell","year":"2000","unstructured":"Lell B, Faucher JF, Missinou MA, Borrmann S, Dangelmaier O, Horton J, et al. Malaria chemoprophylaxis with tafenoquine: a randomised study. Lancet. 2000;355(9220):2041\u20135.","journal-title":"Lancet"},{"issue":"11","key":"9112_CR50","doi-asserted-by":"publisher","first-page":"e00711","DOI":"10.1128\/AAC.00711-18","volume":"62","author":"N Thakkar","year":"2018","unstructured":"Thakkar N, Green JA, Koh GCKW, Duparc S, Tenero D, Goyal N. Population pharmacokinetics of tafenoquine, a novel antimalarial. Antimicrob Agents Chemother. 2018;62(11):e00711-e718.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"9112_CR51","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1128\/AAC.48.11.4075-4083.2004","volume":"48","author":"JK Baird","year":"2004","unstructured":"Baird JK. Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother. 2004;48(11):4075\u201383.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"9112_CR52","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/1475-2875-10-212","volume":"10","author":"GS Dow","year":"2011","unstructured":"Dow GS, Gettayacamin M, Hansukjariya P, Imerbsin R, Komcharoen S, Sattabongkot J, et al. Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). Malar J. 2011;10(1):212.","journal-title":"Malar J"},{"key":"9112_CR53","unstructured":"DAIDS Regulatory Support Center (RSC) [Internet]. [cited 2023 Mar 27]. Available from: https:\/\/rsc.niaid.nih.gov\/"},{"issue":"5","key":"9112_CR54","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1128\/JCM.43.5.2435-2440.2005","volume":"43","author":"KA Mangold","year":"2005","unstructured":"Mangold KA, Manson RU, Koay ESC, Stephens L, Regner M, Thomson RB, et al. Real-time PCR for detection and identification of Plasmodium spp. J Clin Microbiol. 2005;43(5):2435\u201340.","journal-title":"J Clin Microbiol"},{"issue":"1","key":"9112_CR55","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12936-018-2201-0","volume":"17","author":"M Gruenberg","year":"2018","unstructured":"Gruenberg M, Moniz CA, Hofmann NE, Wampfler R, Koepfli C, Mueller I, et al. Plasmodium vivax molecular diagnostics in community surveys: pitfalls and solutions. Malar J. 2018;17(1):55.","journal-title":"Malar J"},{"issue":"1","key":"9112_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-022-04352-2","volume":"5","author":"H Trimarsanto","year":"2022","unstructured":"Trimarsanto H, Amato R, Pearson RD, Sutanto E, Noviyanti R, Trianty L, et al. A molecular barcode and web-based data analysis tool to identify imported Plasmodium vivax malaria. Commun Biol. 2022;5(1):1\u201310.","journal-title":"Commun Biol"},{"issue":"1","key":"9112_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13412-x","volume":"10","author":"AR Taylor","year":"2019","unstructured":"Taylor AR, Watson JA, Chu CS, Puaprasert K, Duanguppama J, Day NPJ, et al. Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. Nat Commun. 2019;10(1):5595.","journal-title":"Nat Commun"},{"issue":"7","key":"9112_CR58","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/infdis\/jiaa527","volume":"225","author":"SK Tessema","year":"2022","unstructured":"Tessema SK, Hathaway NJ, Teyssier NB, Murphy M, Chen A, Aydemir O, et al. Sensitive, highly multiplexed sequencing of microhaplotypes from the Plasmodium falciparum heterozygome. J Infect Dis. 2022;225(7):1227\u201337.","journal-title":"J Infect Dis"},{"key":"9112_CR59","doi-asserted-by":"crossref","unstructured":"MAM 2020: growing strong on the 20th anniversary. Trends Parasitol. 2020;36(6):487\u201394.","DOI":"10.1016\/j.pt.2020.04.001"},{"key":"9112_CR60","unstructured":"Auburn S, Kleinecke M, Rumaseb A, Sutanto E, Trimarsanto H, Hoon KS, et al. Microhaplotype deep sequencing assays to capture Plasmodium vivax infection lineages [Internet]. Research Square; 2024 [cited 2024 Oct 31]. Available from: https:\/\/www.researchsquare.com\/article\/rs-5099658\/v1"},{"issue":"32","key":"9112_CR61","doi-asserted-by":"publisher","first-page":"E4438","DOI":"10.1073\/pnas.1501705112","volume":"112","author":"DA Helb","year":"2015","unstructured":"Helb DA, Tetteh KKA, Felgner PL, Skinner J, Hubbard A, Arinaitwe E, et al. Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities. Proc Natl Acad Sci U S A. 2015;112(32):E4438-4447.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"9112_CR62","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41591-020-0841-4","volume":"26","author":"RJ Longley","year":"2020","unstructured":"Longley RJ, White MT, Takashima E, Brewster J, Morita M, Harbers M, et al. Development and validation of serological markers for detecting recent Plasmodium vivax infection. Nat Med. 2020;26(5):741\u20139.","journal-title":"Nat Med"},{"issue":"1","key":"9112_CR63","doi-asserted-by":"publisher","first-page":"e130769","DOI":"10.1172\/jci.insight.130769","volume":"5","author":"A Rosas-Aguirre","year":"2020","unstructured":"Rosas-Aguirre A, Patra KP, Calder\u00f3n M, Torres K, Gamboa D, Arocutipa E, et al. Anti-MSP-10 IgG indicates recent exposure to Plasmodium vivax infection in the Peruvian Amazon. JCI Insight. 2020;5(1):e130769.","journal-title":"JCI Insight."},{"issue":"3","key":"9112_CR64","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3390\/pathogens10030282","volume":"10","author":"E Villasis","year":"2021","unstructured":"Villasis E, Garro K, Rosas-Aguirre A, Rodriguez P, Rosado J, Gave A, et al. PvMSP8 as a novel Plasmodium vivax malaria sero-marker for the Peruvian Amazon. Pathogens. 2021;10(3):282.","journal-title":"Pathogens"},{"issue":"14","key":"9112_CR65","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1038\/s41598-024-52239-5","volume":"2","author":"B Fernandez-Camacho","year":"2024","unstructured":"Fernandez-Camacho B, Pe\u00f1a-Calero B, Guillermo-Roman M, Ruiz-Cabrejos J, Barboza JL, Bartolini-Arana L, et al. Malaria seroepidemiology in very low transmission settings in the Peruvian Amazon. Sci Rep. 2024;2(14):2806.","journal-title":"Sci Rep"},{"key":"9112_CR66","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/B978-0-12-800099-1.00003-X","volume":"84","author":"LS Tusting","year":"2014","unstructured":"Tusting LS, Bousema T, Smith DL, Drakeley C. Measuring changes in Plasmodium falciparum transmission: precision, accuracy and costs of metrics. Adv Parasitol. 2014;84:151\u2013208.","journal-title":"Adv Parasitol"},{"issue":"11","key":"9112_CR67","doi-asserted-by":"publisher","first-page":"e113357","DOI":"10.1371\/journal.pone.0113357","volume":"9","author":"MG Cunha","year":"2014","unstructured":"Cunha MG, Silva ES, Sep\u00falveda N, Costa SPT, Saboia TC, Guerreiro JF, et al. Serologically defined variations in malaria endemicity in Par\u00e1 state, Brazil. PLoS One. 2014;9(11):e113357.","journal-title":"PLoS One."},{"issue":"1","key":"9112_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-017-1945-2","volume":"16","author":"RA Simmons","year":"2017","unstructured":"Simmons RA, Mboera L, Miranda ML, Morris A, Stresman G, Turner EL, et al. A longitudinal cohort study of malaria exposure and changing serostatus in a malaria endemic area of rural Tanzania. Malar J. 2017;16(1):309.","journal-title":"Malar J"},{"key":"9112_CR69","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1201\/9781584888178","volume-title":"Cluster randomised trials","author":"RJ Hayes","year":"2009","unstructured":"Hayes RJ, Moulton LH. Cluster randomised trials. New York: Chapman and Hall\/CRC; 2009. p. 338."},{"issue":"12","key":"9112_CR70","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1093\/infdis\/jiw416","volume":"214","author":"TP Eisele","year":"2016","unstructured":"Eisele TP, Bennett A, Silumbe K, Finn TP, Chalwe V, Kamuliwo M, et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in Southern Province Zambia: A Cluster-Randomized Controlled Trial. J Infect Dis. 2016;214(12):1831\u20139.","journal-title":"J Infect Dis"},{"issue":"10233","key":"9112_CR71","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/S0140-6736(20)30470-0","volume":"395","author":"MS Hsiang","year":"2020","unstructured":"Hsiang MS, Ntuku H, Roberts KW, Dufour MSK, Whittemore B, Tambo M, et al. Effectiveness of reactive focal mass drug administration and reactive focal vector control to reduce malaria transmission in the low malaria-endemic setting of Namibia: a cluster-randomised controlled, open-label, two-by-two factorial design trial. Lancet. 2020;395(10233):1361\u201373.","journal-title":"Lancet"},{"issue":"24","key":"9112_CR72","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1002\/sim.7410","volume":"36","author":"F Li","year":"2017","unstructured":"Li F, Turner EL, Heagerty PJ, Murray DM, Vollmer WM, DeLong ER. An evaluation of constrained randomization for the design and analysis of group-randomized trials with binary outcomes. Stat Med. 2017;36(24):3791\u2013806.","journal-title":"Stat Med"},{"issue":"19","key":"9112_CR73","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1002\/sim.1296","volume":"21","author":"SJ Pocock","year":"2002","unstructured":"Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med. 2002;21(19):2917\u201330 (Oct 15;).","journal-title":"Stat Med"},{"issue":"1","key":"9112_CR74","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1740774511420743","volume":"9","author":"MA Hern\u00e1n","year":"2012","unstructured":"Hern\u00e1n MA, Hern\u00e1ndez-D\u00edaz S. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials. 2012;9(1):48\u201355.","journal-title":"Clin Trials"},{"key":"9112_CR75","doi-asserted-by":"crossref","unstructured":"Benjamin-Chung J, Arnold BF, Kennedy CJ, Mishra K, Pokpongkiat N, Nguyen A, et al. Impact of a city-wide school-located influenza vaccination program over four years on vaccination coverage, school absences, and laboratory-confirmed influenza: a prospective matched cohort study. 2019 Dec 4 [cited 2023 Mar 27]; Available from: https:\/\/escholarship.org\/uc\/item\/6ts9v3t5","DOI":"10.1101\/19013151"},{"issue":"1","key":"9112_CR76","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1093\/ije\/dyx201","volume":"47","author":"J Benjamin-Chung","year":"2018","unstructured":"Benjamin-Chung J, Arnold BF, Berger D, Luby SP, Miguel E, Colford JM Jr, et al. Spillover effects in epidemiology: parameters, study designs and methodological considerations. Int J Epidemiol. 2018;47(1):332\u201347.","journal-title":"Int J Epidemiol"},{"issue":"8","key":"9112_CR77","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/aje\/kwy046","volume":"187","author":"J Benjamin-Chung","year":"2018","unstructured":"Benjamin-Chung J, Amin N, Ercumen A, Arnold BF, Hubbard AE, Unicomb L, et al. A randomized controlled trial to measure spillover effects of a combined water, sanitation, and handwashing intervention in rural Bangladesh. Am J Epidemiol. 2018;187(8):1733\u201344.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"9112_CR78","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0049124112437535","volume":"41","author":"PM Aronow","year":"2012","unstructured":"Aronow PM. A general method for detecting interference between units in randomized experiments. Sociol Methods Res. 2012;41(1):3\u201316.","journal-title":"Sociol Methods Res"},{"issue":"4","key":"9112_CR79","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/inthealth\/ihw027","volume":"8","author":"PY Cheah","year":"2016","unstructured":"Cheah PY, White NJ. Antimalarial mass drug administration: ethical considerations. Int Health. 2016;8(4):235\u20138.","journal-title":"Int Health"},{"issue":"1","key":"9112_CR80","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12916-015-0302-y","volume":"13","author":"AM Siqueira","year":"2015","unstructured":"Siqueira AM, Lacerda MV, Magalh\u00e3es BML, Mour\u00e3o MP, Melo GC, Alexandre MA, et al. Characterization of Plasmodium vivax-associated admissions to reference hospitals in Brazil and India. BMC Med. 2015;13(1):57.","journal-title":"BMC Med"},{"issue":"1","key":"9112_CR81","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4269\/ajtmh.12-0610","volume":"91","author":"AM Quispe","year":"2014","unstructured":"Quispe AM, Pozo E, Guerrero E, Durand S, Baldeviano GC, Edgel KA, et al. Plasmodium vivax hospitalizations in a monoendemic malaria region: severe vivax malaria? Am J Trop Med Hyg. 2014;91(1):11\u20137.","journal-title":"Am J Trop Med Hyg"},{"issue":"6","key":"9112_CR82","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.4269\/ajtmh.14-0652","volume":"93","author":"F Llanos-Chea","year":"2015","unstructured":"Llanos-Chea F, Rosas A, Vinetz JM, Mart\u00ednez D, Samalvides F, Llanos-Cuentas A. Characteristics of travel-related severe Plasmodium vivax and Plasmodium falciparum malaria in individuals hospitalized at a tertiary referral center in Lima, Peru. Am J Trop Med Hyg. 2015;93(6):1249\u201353.","journal-title":"Am J Trop Med Hyg"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09112-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09112-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09112-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T01:05:53Z","timestamp":1760490353000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09112-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9112"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09112-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5594891\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"6 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol has been approved by National Institute of Health (INS) in Peru, Universidad Peruana Cayetano Heredia Institutional Review Board, and by University of California San Francisco Institutional Review Board. The trial is registered at clinicaltrials.gov (NCT05690841). Consent will be obtained from all study participants prior to conduct of any study activities.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no competing interests. Jade Benjamin-Chung is a Chan Zuckerberg Biohub Investigator.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"408"}}